Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18444223 | 1.00 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL14919644 | 1.00 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL14921393 | 1.00 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL18444225 | 1.00 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL14921296 | 1.00 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL30511498 | 0.91 | ALOX5 (0.41) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL17550484 | 0.89 | BTN3A1 (0.40) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL30583779 | 0.88 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL16258629 | 0.88 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 | |
| SCHEMBL16258631 | 0.88 | MEN1 (0.42) | MEN1KMT2AALOX5PTGESALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3831836-B1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2023-09-06 | — | — | EP | disclosed |
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2023-05-25 | — | — | US | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3831388-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831836-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210147456-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-3331894-B1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INT BIOTECH LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200352966-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2020-11-12 | — | — | US | disclosed |
| US-10548913-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3331894-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | Metro International Biotech, LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2018-05-31 | — | — | US | disclosed |
| US-9919003-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2018-03-20 | — | — | US | disclosed |
| US-9855289-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170290850-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INTERNATIONAL BIOTECH, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170189434-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INTERNATIONAL BIOTECH, LLC | 2017-07-06 | — | — | US | disclosed |
| WO-2017024255-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | MEN1 3636/4885KMT2A 3822/4885ALOX5 247/4885 |
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | MEN1 950/4885KMT2A 2370/4885ALOX5 1527/4885 |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | MEN1 2712/4885KMT2A 4442/4885ALOX5 1869/4885 |
| US-20210147456-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | MEN1 2712/4885KMT2A 4442/4885ALOX5 1869/4885 |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | MEN1 950/4885KMT2A 2370/4885ALOX5 1527/4885 |
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | MEN1 950/4885KMT2A 2370/4885ALOX5 1527/4885 |
| US-20200352966-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | MEN1 950/4885KMT2A 2370/4885ALOX5 1527/4885 |
| US-10548913-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | MEN1 950/4885KMT2A 2370/4885ALOX5 1527/4885 |
| US-20170290850-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | MEN1 950/4885KMT2A 2370/4885ALOX5 1527/4885 |
| US-20170189434-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | MEN1 950/4885KMT2A 2370/4885ALOX5 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.